Use of MIR101 or MIR128 in the treatment of seizure disorders
AssigneeOvid Therapeutics Inc.
InventorMatthew During
Life of this patent
Estimating the term…
Loading patent…
AssigneeOvid Therapeutics Inc.
InventorMatthew During
Estimating the term…
Methods of treating a seizure disorder in a patient in need thereof are provided which include delivering to the patient an effective amount of a composition that increases the level of microRNA-101 molecules in brain cells of the patient. Methods of treating a seizure disorder in a patient in need thereof are provided which include delivering to the patient an effective amount of a composition that increases the level of microRNA-128 molecules in brain cells of the patient. Methods of treating a seizure disorder in a patient in need thereof are provided which include administering a vector encoding microRNA-101, pri-miR101 or pre-miR101 to the patient. Methods of treating a seizure disorder in a patient in need thereof are provided which include administering a vector encoding microRNA-128, pri-miR128 or pre-miR128 to the patient. In embodiments, increased levels of microRNA-101 and/or microRNA-128 cause improvement in one or more symptoms of the seizure disorder.
A method of treating epilepsy in a patient in need thereof comprising administering to the patient an effective amount of a pharmaceutical composition that increases the level of microRNA-101 molecules in the patient's brain.
Dependencies are inferred from the claim text.